Sanofi SA (LTS:0A2V)
$ 49 0 (0%) Market Cap: 122.85 Bil Enterprise Value: 141.18 Bil PE Ratio: 28.19 PB Ratio: 1.63 GF Score: 87/100

Sanofi SA at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 03:40PM GMT
Keyur Parekh
Goldman Sachs Group Inc., Research Division - Equity Analyst

Good morning, and thank you all for joining us. My name is Keyur Parekh, and I cover Sanofi for Goldman Sachs. Bill, thank you very much for joining us.

William J. Sibold
Sanofi - EVP of Genzyme

Pleasure to be here.

Keyur Parekh
Goldman Sachs Group Inc., Research Division - Equity Analyst

The business has been -- [albeit just China was down], kind of the business has been in a great shape this year, and if you want to make a few introductory comments on how do you see the business kind of for the next kind of year or so and then we can go straight to Q&A from there?

William J. Sibold
Sanofi - EVP of Genzyme

Yes. That's great. So yes, look, we're off to a strong first quarter and really delivering on this goal of return to growth for Sanofi. At constant exchange rates from a sales and EPS perspective, we grew 4.2% and 9.4%, respectively. So one of the things I was excited about was double

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot